Jubilant Pharmova Limited (JUBLPHARMA) — FY26 Annual Report | 1 August 2026

· NSE 🔴 High Importance Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
48th Annual General Meeting (AGM) of Jubilant Pharmova Limited scheduled for August 26, 2026, via video conferencing.
🔄 What Changed
Dividend declaration of ₹5 per share; reappointment of directors Hari S. Bhartia and Arjun Shanker Bhartia; transfer of 61,259 unclaimed dividend shares to IEPF; updated e-voting procedures and KYC compliance requirements.
🔮 What's Next
The AGM will be conducted via video conferencing on August 26, 2026, at 11:00 a.m. (IST), with e-voting open from August 23 to 25, 2026. Shareholders must complete KYC and update PAN by August 14, 2026, to receive dividends without TDS.
💡 Investor Takeaway
Shareholders must complete KYC and update PAN by August 14, 2026, to claim the ₹5 per share dividend without TDS deductions.

The filing announces the 48th Annual General Meeting (AGM) of Jubilant Pharmova Limited scheduled for August 26, 2026, via video conferencing. It includes the AGM notice, annual report for FY 2025-26, and details on e-voting, dividend declaration (₹5 per share), director reappointments, and compliance with SEBI and MCA regulations. Documents are accessible via the company website and stock exchanges. Additional disclosures cover TDS on dividends, KYC requirements, investor education initiatives, and unclaimed dividend transfers to the IEPF Authority.

📄 View Original Announcement (PDF)

About Jubilant Pharmova Limited (JUBLPHARMA)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹14,469.9 Cr P/E: 40.9 ROE: 5.0% ROCE: 7.4% Div Yield: 0.55%

View full JUBLPHARMA stock details →

📡 Get AI alerts when JUBLPHARMA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track JUBLPHARMA — Free

📊 More JUBLPHARMA filings

See all JUBLPHARMA filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when JUBLPHARMA files new disclosures

Track JUBLPHARMA filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track JUBLPHARMA — Free

Free account · 2 AI queries/day